Form 4: Quince Therapeutics Director Acquires Stock Options in Lieu of Cash Retainer

Director David Lamond acquired 47,587 stock options in Quince Therapeutics in lieu of his 2025 annual cash retainer.

Summary

• David Lamond, a director at Quince Therapeutics, acquired 47,587 stock options on January 2, 2025.
• These options were granted in lieu of his annual director cash retainer for 2025.
• The options have an exercise price of $1.88 per share.
• The options vest in equal quarterly installments over a one-year period.
• The options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive as it aligns director interests with shareholders. There is no indication of any negative sentiment.

Positives

• The director's decision to take stock options instead of cash may indicate confidence in the company's future performance.
• The vesting schedule of one year encourages the director to remain engaged with the company.

Management Comments

• The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.

Industry Context

This is a standard practice for compensating board members, particularly in growth-oriented companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the biotechnology industry, often used to incentivize performance and align interests with shareholders.
• Many companies, such as those in the NASDAQ Biotechnology Index (NBI), use similar compensation structures for their board members.
• The vesting schedule of one year is also typical, ensuring that directors remain engaged and committed to the company's long-term success.

Stakeholder Impact

• Shareholders may view this as a positive sign, as it aligns the director's interests with the company's performance.
• The director is incentivized to contribute to the company's success to realize the value of the stock options.

Key Dates

Keywords

stock options, director compensation, insider trading, Quince Therapeutics, QNCX, executive compensation, equity